A Study to Evaluate SAGE-217 in Participants With Essential Tremor

Summary

This study is a three-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in adult participants with essential tremor.

Timeline

Start

2017-03-24

Primary completion

2017-11-22

Completion

2017-12-05

Outcome

Missed primary endpoint

registry analysis (superiority test); Part B: Placebo vs Part B: SAGE-217 Capsules; p = 0.9143; Least Squares Mean Difference 0.02 (95% CI -0.44 to 0.49); NCT02978781 ↗

Drugs

Indications